1. Home
  2. SOWG vs CING Comparison

SOWG vs CING Comparison

Compare SOWG & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

N/A

Current Price

$2.31

Market Cap

69.9M

ML Signal

N/A

CING

Cingulate Inc.

N/A

Current Price

$4.91

Market Cap

70.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOWG
CING
Founded
2010
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.9M
70.2M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
SOWG
CING
Price
$2.31
$4.91
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $21.20
AVG Volume (30 Days)
5.3K
★ 106.2K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.10
$3.16
52 Week High
$15.90
$11.89

Technical Indicators

Market Signals
Indicator
SOWG
CING
Relative Strength Index (RSI) 46.28 49.31
Support Level $2.10 $4.73
Resistance Level $2.62 $5.31
Average True Range (ATR) 0.18 0.30
MACD 0.05 0.07
Stochastic Oscillator 82.29 49.49

Price Performance

Historical Comparison
SOWG
CING

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: